IFF to Webcast Fireside Chat at Barclays Global Consumer Conference on Sept. 10 August 18, 2026 IFF (NYSE: IFF) today announced that Chief Executive Officer Erik Fyrwald will participate in a fireside chat at the Barclays Global Consumer Conference on Thursday, Sept. 10, 2026 at 945 a.m. ET. Investors may access the live webcast on the Company’s website at ir.iff.com. For those unable to listen to the live webcast, a recorded [...]
Xsolla Partner Network Expands Verified Creator Partnerships and Unifies Campaign Management Ahead of gamescom 2026 August 18, 2026 Developers Gain Vetted Creator Partnerships And A Single Campaign Workflow, Managed From The Publisher Account They Already Use
Elite Cloud Customers to Outnumber On-Premises for the First Time in Company History as Law Firms Build for AI August 17, 2026 With over 120 firms live in the cloud, Elite's platform has now processed $145 billion in billing transactions — and customers are collecting payment nearly twice as fast as the industry average
Xsolla Adds 15+ New Local Payment Methods, Letting Game Developers Reach Players Across Asia-Pacific, Europe, and the Americas August 17, 2026 Now Live: Mandiri, ShopeePay, LINE Pay, Octopus, Konbini 7/11, China UnionPay, Zip Co, Wero, Pay by Bank, FLOA Pay BNPL, Bancomat Pay, MyBank, IRIS Commerce, CliQ, and Aeropay
Lattice to Deliver Keynote at 2026 OCP Global Summit August 12, 2026 Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced that Lattice will deliver a keynote at the 2026 OCP Global Summit. Ford Tamer, President and CEO of Lattice Semiconductor, will take the stage with Sanjoy Maity, Senior Vice President, AMI Business Unit Leader, Lattice Semiconductor. Together, they will discuss the [...]
Conga Announces Netflix Documentary Star and Survival Expert Chris Lemons as Its Featured Speaker at Conga Connection 2026 August 12, 2026 The Annual Event Comes to Amsterdam This October, Bringing Together European Revenue, Commercial, and Operations Leaders to Accelerate What Matters
Allegion to Attend 2026 Mizuho Industrials & Chemicals Conference August 5, 2026 Allegion plc (NYSE: ALLE) Senior Vice President and Chief Financial Officer Mike Wagnes will discuss the company’s long-term strategy at the 2026 Mizuho Industrials & Chemicals Conference on Wednesday, August 12. The conference will be held at the Mandarin Oriental in New York City. About Allegion At Allegion (NYSE: ALLE), we design and manufacture innovative [...]
Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026 July 29, 2026 Superiority data from LATA, together with OPERA findings, add to the clinical and real-world evidence base for long-acting injectable Cabenuva Six-month follow-up CLARITY data further reinforce a more favourable injection experience with long-acting cabotegravir compared with lenacapavir after a single dose; additional studies showcase high real-world adherence and a preference for Apretude among previous oral PrEP users EXTEND 4M explores a new investigational intramuscular cabotegravir formulation dosed three times a year for HIV prevention, as part of broader long-acting pipeline data
Grindr for Equality Commits to Connecting 10M to HIV Prevention by 2028 July 27, 2026 New report finds PrEP awareness is high but access is low, as global HIV funding shrinks Grindr steps up
ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults; alongside INSTI-powered long-acting injectable innovation at AIDS 2026 July 21, 2026 VOGUE is the first head-to-head, randomised daily orals study comparing 2-drug regimen Dovato with 3-drug regimen Biktarvy in treatment-naïve adults living with HIV Real-world OPERA data continues to strengthen the evidence base for Cabenuva, the only complete long-acting injectable HIV treatment regimen Six-month results from the CLARITY study will report participant experience and acceptability of long-acting cabotegravir versus lenacapavir injections after a single dose in HIV-negative adults